Therefore, our results uncover the overarching role of CARMIL2-CARD11–driven signals among those triggered by CD28 in vivo and we demonstrated that they can be exploited to generate potent tumor-specific CD8+ T cells that do not require CD28 engagement and thereby escape to both PD-1 and CTLA-4 inhibition. The gene discussed is CD8A; the disease is neoplasm.